India pharmaceutical market logs 6.6% yoy revenue growth in November: India Ratings and Research
![](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2021/12/7c8656ab90e69ca03e5a8d40b1fb8304.png)
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Credit rating agency, India Ratings and Research (Ind-Ra) in its latest report has showed the 6.6% yoy revenue growth in India’s pharmaceutical market (IPM) during November 2021, led by improving growth trends in chronic therapies, namely cardiac 6% yoy (October 2021: down 1% yoy) and anti-diabetic 6% yoy (October 2021: up 1% yoy ).
The report further noted that acute therapies namely gastro-intestinal, respiratory and pain/analgesics continued to witness strong growth, aided by the low base impact. During November 2021, volumes were flat yoy (October 2021: declined 1.6% yoy), while price growth was 5.4% (5.3%) and new products launches were 1.2% (1.4%), driven by acute therapy products.
According to the report, acute therapies such as gastro, respiratory and pain/analgesics witnessed sales growth of 13.1% yoy, 16.3% yoy and 17.3% yoy respectively. Growth improvement was observed in chronic therapies during the month, with cardiac growing 6.3% yoy and anti-diabetic reporting 6.0% yoy growth.
![](https://portfolio.investmentguruindia.com/uploads/news/Ajmera Realty.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Pharma Sector 56.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/MoU Signing (1) 23.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Gv_Hotel.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/ShaktikantDas080324.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Realestate04.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Maruti Suzuki 25.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/FMCG4.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Arpit Mehrotra, Managing Director, Office services, India, Colliers.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Finance.jpg)
Tag News
![](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/09/c5541407585e9dfdc52f905c92d59e61.jpg)
Monthly Debt Market Update, September 2023: CareEdge Ratings
![Quote on RBI decision to discontinue the incremental cash reserve ratio (CRR) By Dr. Manoranjan Sharma, Infomerics Ratings](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/09/3fb5395769079c26d9056714d034c581.jpg)
![Governance mechanism, customer-centricity can help in fintech ecosystem sustainable growth: Ajay Chaudhary](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/09/07e25a74a16d5c092d179215565d0295.jpg)
![3 Centres of Excellence set up by TIDCO finding good traction: Tamil Nadu Minister](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2023/09/e6ff15c8d3a72074f69cb881ab6584e7.jpg)